United Therapeutics CEO Martine Rothblatt Exercises Stock Options and Executes Planned Share Sales

CEO Option Exercise and Coordinated Share Sale Activity

Martine A. Rothblatt, who serves as Chairperson and Chief Executive Officer of United Therapeutics Corporation, exercised 9,500 stock options on July 24, 2026, at an exercise price of $135.42 per share, according to the company's disclosure. The filing states that these options, which expire on March 15, 2027, were exercised pursuant to a pre-arranged trading plan established under Securities and Exchange Commission Rule 10b5-1(c). The exercise generated 9,500 shares of common stock for Rothblatt's account.

On the same date, Rothblatt executed a series of coordinated share sales totaling 8,577 shares across eight separate transactions. The sales occurred at weighted average prices that ranged from $528.72 per share in the first transaction to $535.03 per share in the final trade. Each individual sale involved multiple trades executed at slightly varying prices throughout the trading day, with the reported figures reflecting the weighted average price for each batch of shares sold. The filing indicates that Rothblatt undertakes to provide detailed information regarding the exact number of shares and specific prices at which each transaction was executed upon request to the SEC staff, the issuer, or company security holders.

Pre-Arranged Trading Plan Framework and Authorization

The disclosure confirms that all transactions executed on July 24, 2026, were undertaken pursuant to a Rule 10b5-1 trading plan that Rothblatt adopted on November 7, 2025. Under Securities and Exchange Commission regulations, Rule 10b5-1(c) permits directors, officers, and other company insiders to establish pre-arranged trading plans that provide an affirmative defense against liability for trading on the basis of material nonpublic information. The adoption and execution of such plans must be documented and made public through insider transaction disclosures.

According to the filing, the trading plan will continue until the earlier of two specified conditions: either the exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026. This structure indicates a substantial commitment by Rothblatt to execute a predetermined series of equity transactions over an eight-month period. The plan represents a systematic approach to portfolio diversification and liquidity management by the company's top executive, allowing for orderly sales without concern regarding the timing of material corporate information.

Beneficial Ownership Holdings Following Transaction Settlement

Following completion of the July 24, 2026, transactions, Rothblatt maintained significant indirect beneficial ownership of United Therapeutics shares through various family trust arrangements. The filing indicates that Rothblatt held 324,443 shares indirectly through trusts as to which Rothblatt shares investment power and is a beneficiary. In addition, Rothblatt held 40,513 shares directly and maintained indirect ownership of an additional 249,108 shares held in family trusts where Rothblatt's spouse is sole trustee and sole beneficiary or co-trustee with power to revoke.

The company's disclosure also reflects that Rothblatt's spouse held 166 shares indirectly through trusts and 45,596 additional shares through other trust arrangements. Rothblatt maintained beneficial ownership of 8,902 shares through a family trust where Rothblatt serves as sole trustee and sole beneficiary or co-trustee with power to revoke. In total, the combined direct and indirect beneficial ownership across all trust arrangements and spousal holdings demonstrates substantial continued equity participation by the company's CEO in United Therapeutics following the transaction activity.

Stock Option Holdings and Expiration Timeline

The disclosure reveals that Rothblatt maintained derivative securities in the form of stock options following the July 24, 2026, transactions. Specifically, the filing states that Rothblatt held 274,910 stock options indirectly through family trusts as to which Rothblatt shares investment power and is a beneficiary. These options represent substantial additional upside exposure to United Therapeutics stock price appreciation prior to their expiration on March 15, 2027.

The March 15, 2027, expiration date creates a meaningful deadline by which remaining options must either be exercised or will expire worthless. Given that the pre-arranged trading plan under which Rothblatt is executing transactions contemplates exercise of up to 1,734,410 total stock options before the end of 2026, investors may be watching whether Rothblatt continues to exercise options and sell shares according to the pre-established schedule. The options exercised on July 24, 2026, carried an exercise price of $135.42 per share, substantially below the share prices at which sales occurred on the same date.

Multiple Weighted Average Sales and Price Execution Details

The filing provides transparency regarding the execution of eight separate share sale transactions on July 24, 2026, with each sale reported at a weighted average price. The first transaction involved the sale of 820 shares at a weighted average price of $528.72, with individual trades executed at prices ranging from $528.16 to $528.83. The second transaction sold 2,285 shares at a weighted average price of $530.45, executed at prices ranging from $529.71 to $530.70 per share.

Subsequent transactions reflected the prevailing market conditions during the trading day. The third sale of 1,115 shares occurred at a weighted average price of $531.10, with trades executed between $530.72 and $531.64. The fourth transaction sold 2,719 shares at $532.27 per share, with individual trades between $531.74 and $532.72. The fifth sale involved 1,818 shares at $533.20, the sixth sold 630 shares at $534.39, and the seventh transaction involved 113 shares at $535.03. This graduated pricing pattern suggests that shares were sold progressively throughout the trading session, potentially allowing the market to absorb the sales without significant downward price pressure while capturing incremental price improvements as the day progressed.

Trust Structures and Indirect Ownership Arrangements

The disclosure itemizes the various trust structures through which Rothblatt maintains indirect beneficial ownership of United Therapeutics securities. The filing distinguishes among several categories of trust arrangements based on the nature of Rothblatt's relationship to each trust and the roles of family members. A substantial portion of Rothblatt's holdings are classified as indirect ownership held through trusts as to which Rothblatt shares investment power and Rothblatt and/or immediate family members are beneficiaries. This structure typically indicates discretionary investment authority shared among multiple family members.

Additional holdings are characterized as trusts where Rothblatt's spouse serves as sole trustee and sole beneficiary or as co-trustee and settlor with power to revoke. These arrangements typically reflect estate planning strategies that maintain spousal involvement in investment decision-making. Rothblatt also maintains trusts where Rothblatt serves as sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. The aggregate effect of these multiple trust arrangements demonstrates the use of sophisticated estate planning structures to hold and manage equity ownership in the company, a common practice among senior executives of public corporations.

Regulatory Compliance and Certification

The filing was executed on July 27, 2026, by John S. Hess, Jr., acting under a power of attorney granted by Rothblatt. The power of attorney authorization permits Hess to sign and file required disclosure documents on behalf of the CEO, a common administrative arrangement at publicly traded companies. The filing includes standard SEC certifications regarding the accuracy and completeness of the information provided, with acknowledgment that intentional misstatements or omissions constitute federal criminal violations under 18 U.S.C. Section 1001 and 15 U.S.C. Section 78ff(a).

The disclosure confirms that the reported transactions fall within the scope of Section 16(a) of the Securities Exchange Act of 1934, requiring reporting by officers, directors, and substantial shareholders of their securities transactions. The checkbox indicating that this exercise of stock options and sale of resulting shares was made pursuant to a written plan satisfying the affirmative defense conditions of Rule 10b5-1(c) provides clear regulatory authorization for the transactions. This certification is significant because it establishes that the trading activity was pre-planned and therefore does not raise concerns about potential trading on material nonpublic information, a fundamental concern in insider trading regulations.

Market Context and Executive Liquidity Strategy

The transactions executed by Rothblatt on July 24, 2026, represent a significant liquidity event for the CEO, with aggregate sale proceeds from the 8,577 shares sold totaling approximately $4.56 million based on the weighted average sale prices. This activity reflects a deliberate portfolio diversification and liquidity management strategy by the company's top executive. The pre-arranged nature of the trading plan, established in November 2025 and scheduled to continue through year-end 2026, suggests this represents a planned approach to managing CEO equity compensation received through stock options and company grants.

The fact that Rothblatt exercised options at $135.42 and sold shares at prices approximately three to four times higher reflects significant appreciation in the company's stock value since the options were granted. The staggered sale approach implemented on July 24, 2026, with sales occurring progressively throughout the trading session and at prices that improved during the day, demonstrates a execution approach designed to optimize pricing while completing a substantial volume of sales. The regulatory framework permitting such pre-arranged plans reflects the SEC's acknowledgment that orderly, disclosed insider transactions by executives serve important liquidity and diversification functions.

Subsequent Trading Plan Administration and Timeline

The pre-arranged trading plan under which these transactions were executed remains active and will continue through December 31, 2026, or until Rothblatt exercises a total of 1,734,410 stock options, whichever occurs first. The plan encompasses a substantial number of option exercises contemplated over the remaining months of 2026, suggesting that additional insider transaction disclosures will likely be filed as Rothblatt continues to exercise options and sell shares according to the pre-established schedule. Investors monitoring executive transactions may receive regular updates regarding the progress and execution of this trading plan through periodic Form 4 filings.

The expiration date of March 15, 2027, for the underlying stock options creates a natural deadline for option exercise activity, as any options not exercised by that date will expire worthless. The December 31, 2026, termination date specified in the trading plan ensures that option exercise and share sale activity will be substantially concluded before the year's end, allowing Rothblatt to lock in pricing and realize liquidity from the planned transactions before the final quarter of the year. This timeline provides a clear administrative framework for understanding the expected duration and scope of the CEO's equity diversification activity.